Loading…

Pharmacokinetics and pharmacodynamics of cardiovascular drugs in chronic heart failure

Abstract Pharmacotherapy in chronic heart failure (HF) is challenging, due to the diverse neuroendocrine, inflammatory, metabolic and immunological mechanisms involved in its pathogenesis, the presence of co-morbidities and use of multiple therapies. Further, physiological parameters influencing dru...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cardiology 2016-12, Vol.224, p.191-198
Main Authors: Lainscak, Mitja, MD, PhD, FESC, FHFA, Vitale, Cristiana, MD, PhD, Seferovic, Petar, MD, PhD, Spoletini, Ilaria, PhD, Trobec, Katja Cvan, PhD, Rosano, Giuseppe M.C., MD, PhD, FESC, FHFA
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Pharmacotherapy in chronic heart failure (HF) is challenging, due to the diverse neuroendocrine, inflammatory, metabolic and immunological mechanisms involved in its pathogenesis, the presence of co-morbidities and use of multiple therapies. Further, physiological parameters influencing drug pharmacokinetics (PKs) and pharmacodynamics (PDs) may be altered in patients with HF. There is growing evidence that the disease-induced physiological changes may influence the PKs and PDs of all drugs used in patients with HF. Therapeutic approaches should consider all factors that might influence the response to treatment and dosage should be tailored to individual patients. Hence, further studies are required to understand the PK and PD differences between chronic HF patients and healthy subjects. Because PK is difficult to be assessed in the individual patient with HF, PD effects should be used to tailor therapy in patients with HF.
ISSN:0167-5273
1874-1754
DOI:10.1016/j.ijcard.2016.09.015